Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
April, 2026
April 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
27282930  
Carlos Andrés Vergara Sánchez: Insights From the POLY-ACS Trial on Post-ACS Medication Adherence
Carlos Andrés Vergara Sánchez/LinkedIn
Mar 11, 2026, 15:10

Carlos Andrés Vergara Sánchez: Insights From the POLY-ACS Trial on Post-ACS Medication Adherence

Carlos Andrés Vergara Sánchez, Chief Cardiovascular Disease Fellow at Mayo Clinic College of Medicine and Science, shared a post on LinkedIn about a recent article by Juan David Coellar et al, adding:

“Simplifying Post‑ACS Care: Insights from the POLY‑ACS Trial.

Medication adherence after ACS remains one of the biggest barriers to preventing recurrent events.

A new pilot study, POLY‑ACS, explored whether simplifying therapy into a single, once‑daily polypill could make a meaningful difference.

Study at a glance:

  • 2‑center, open‑label pilot RCT
  • 128 ACS patients; median age 58
  • 63 percent Hispanic, 63 percent uninsured, 86 percent safety‑net hospitals
  • Randomized 30 days post‑discharge
  • Intervention: Polypill (ASA + Rosuvastatin 40 mg + clopidogral 75 mg or prasugrel 10 mg)
  • Comparator: Usual care

30‑day outcomes assessed:

  • LDL‑C
  • Platelet reactivity
  • Patient‑reported measures (adherence, satisfaction, QoL)

Key findings:

LDL‑C: Polypill led to a significant within‑group reduction; usual care showed no meaningful change (between‑group Non-significant change).

Platelet Reactivity: Maintained inhibition with polypill; worsened with usual care (between‑group Non-significant).

Patient‑Reported Outcomes:

  • Higher adherence in the polypill arm
  • QoL improved in both groups
  • No change in treatment satisfaction

Between group difference were non-significant across all pt reported outcomes.

Most interesting insight:

Among patients with poor baseline adherence, the polypill produced a meaningful LDL‑C drop, with between‑group differences approaching significance.

Those who struggle most with complex regimens may benefit the most from simplification.

Strengths:

  • Diverse, socioeconomically vulnerable cohort
  • Real‑world antiplatelet regimen included
  • Objective biomarker endpoints

Limitations:

  • 30‑day follow‑up
  • Randomization not at hospital discharge
  • Already optimized baseline LDL (57 mg/dL)

Bottom line:

  • Post‑ACS mortality is still unacceptably high. We have therapies that work — but adherence remains the Achilles’ heel.
  • A polypill won’t solve everything, but it may simplify enough to matter, especially for vulnerable patients.
  • Larger, longer‑term trials with clinical outcomes are needed, but this is a great start towards simplifying treatment and reducing pill burden.

See tweetorial by Nathalie Marrero from UM.

Congratulations to the authors on this important work!”

Title: A polypill strategy for lipid lowering and anti-platelet therapy after acute coronary syndrome: A pilot randomized controlled trial

Authors: Juan David Coellar, Neil Keshvani, Anand K. Jain, Muhammad Shariq Usman, Matthew W. Segar, James W. Miller, Myriam Bustillo-Rubio, Dharam J. Kumbhani, Mohanakrishnan Sathyamoorthy, Javed Butler, Subhash Banerjee, Sean Yates, Thomas J. Wang, Ambarish Pandey

Read the Full Article on American Journal of Preventive Cardiology

Carlos Andrés Vergara Sánchez: Insights From the POLY-ACS Trial on Post-ACS Medication Adherence

Read the Editorial.

Stay updated with Hemostasis Today.

ACS Ambarish Pandey American Journal of Preventive Cardiology Anand K. Jain Carlos Andrés Vergara Sánchez Dharam J. Kumbhani Health Hematology Hemostasis News Hemostasis Today James W. Miller Javed Butler Juan David Coellar Matthew W. Segar Medicine Mohanakrishnan Sathyamoorthy Muhammad Shariq Usman Myriam Bustillo-Rubio Neil Keshvani POLY‑ACS Sean Yates Subhash Banerjee Thomas J. Wang
NewsFeed